Merck Buyout Sparks a Biotech Megatrend

Don’t miss out on potential triple-digit winners every single month... Don’t miss out on potential triple-digit winners every single month...                                                                                                      [Energy and Capital Header] Practical Investment Analysis for the New Energy Economy Merck Buyout Sparks a Biotech Megatrend by Keith Kohl | April 26, 2023 Big Pharma is hunting for the best new treatments for rare diseases. And with a $1.5 trillion war chest of cash at their disposal, these giants are quickly [gobbling up the small biotech firms that are developing them...]( Creating a tsunami of profits for early investors. Take Merck, for instance, the $291 BILLION biotech powerhouse. Merck just bought out Prometheus Biosciences for $10.8 billion to acquire its cutting-edge autoimmune disease treatments. This announcement propelled Prometheus’ stock 70% higher in just THREE days! And this is hardly an isolated example. Big Pharma buyouts are causing several small biotech firms to skyrocket in a short time: - Amgen agreed to acquire Horizon Therapeutics PLC for $27.8 billion, sending Horizon’s stock up 78% in two months. - Johnson & Johnson struck a $16.6 billion deal to acquire Abiomed, causing the stock to jump 50% in only two days. - Pfizer just bought Global Blood Therapeutics for $5.4 billion, whose stock jumped 45% in two days. [But this is only the beginning...]( Because we are witnessing the "Industrial Revolution" in biotech. The massive wave of innovation occurring throughout the sector is the dawn of a Golden Age. Lifesaving medicines and treatments could get to patients much faster — and much more cheaply. We could even witness the cure for cancer... or even the cure for ALL diseases. And with Big Pharma flexing its huge trillion-dollar war chest of cash, scooping up these tiny firms left and right... Biotech is going to be THE hottest place for investors to be in 2023. The best part is that ANYONE can invest in these small biotech stocks. And you don’t need to be a doctor, a biochemist, or even have a college degree. You just need to know which stocks to buy, when to buy them, and when to sell them. And I can show you EXACTLY how to do that with my proprietary [Project Greenlight trading strategy.]( With this strategy, you can predict down to the VERY day when a biotech stock is likely to explode... With signals showing as much as 95% confidence... Giving you a shot at FOUR triple-digit winners every single month! For instance, my readers have already seen gains like: - 3,278% on Aquinox Pharmaceuticals - 190% on ProQR Therapeutics - 212% on Prana Biotechnology - 54% on Dova Pharmaceuticals - 86% on Aldeyra Therapeutics - 87.3% on Viking Therapeutics - 113.3% on Editas Medicine - 669% on Amarin Corporation And that's just to name a few. Now, remember, these are fast-moving gains... Which is why I urge you to act as quickly as possible. We’re talking about more new innovations, drugs, and therapies than ever before... That could set you up to potentially clock massive paydays of 212%, 669%, and even 3,278%... From the most lucrative and fast-paying biotech stocks in the world. And I’m not talking about multibillion-dollar giants like Pfizer, Johnson & Johnson, or Merck... But rather the smaller, innovative companies that are not covered by the mainstream press... The billion-dollar buyout targets for these massive, cash-rich pharmaceutical giants. [Take advantage of this now.]( To your wealth, [Keith Kohl sig] Keith Kohl Investment Director, Topline Trader [Fb]( [Li]( [Tw]( This email was sent to {EMAIL}. You can manage your subscription and get our privacy policy [here](. Energy and Capital, Copyright © 3 East Read Street, Baltimore, MD 21202. Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info [here]( including our privacy policy and information on how to manage your subscription. If you are interested in our other publications, please call our customer service team at [1-877-303-4529](tel:/18773034529).